1. To describe genomic mechanisms of resistance to immunotherapy in prostate cancer.
2. To highlight a critical role for neutrophils in anti-cancer innate immunity induced by a tyrosine kinase inhibitor.
3. To provide an overview of ongoing co-clinical trial efforts with novel immuno-oncology combinations to target PTEN-deficient cancers
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation